{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:44:34Z","timestamp":1787316274507,"version":"build-2736575974"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T00:00:00Z","timestamp":1639440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["TRPY111\/2018 (PI17CIII\/0016)"],"award-info":[{"award-number":["TRPY111\/2018 (PI17CIII\/0016)"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malaria is one of the deadliest diseases in the world, particularly in Africa. As such, resistance to anti-malarial drugs is one of the most important problems in terms of global malaria control. This study assesses the evolution of the different resistance markers over time and the possible influence of interventions and treatment changes that have been made in Equatorial Guinea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 1223 biological samples obtained in the period 1999 to 2019 were included in the study. Screening for mutations in the\n                      <jats:italic>pfdhfr<\/jats:italic>\n                      ,\n                      <jats:italic>pfdhps<\/jats:italic>\n                      ,\n                      <jats:italic>pfmdr1,<\/jats:italic>\n                      and\n                      <jats:italic>pfcrt<\/jats:italic>\n                      genes was carried out by nested PCR and restriction-fragment length polymorphisms (RFLPs), and the study of\n                      <jats:italic>pfk13<\/jats:italic>\n                      genes was carried out by nested PCR, followed by sequencing to determine the presence of mutations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The partially and fully resistant haplotypes (\n                      <jats:italic>pfdhfr<\/jats:italic>\n                      \u2009+\u2009\n                      <jats:italic>pfdhps<\/jats:italic>\n                      ) were found to increase over time. Moreover, in 2019, the fully resistant haplotype was found to be increasing, although its super-resistant counterpart remains much less prevalent. A continued decline in\n                      <jats:italic>pfmdr1<\/jats:italic>\n                      and\n                      <jats:italic>pfcrt<\/jats:italic>\n                      gene mutations over time was also found. The number of mutations detected in\n                      <jats:italic>pfk13<\/jats:italic>\n                      has increased since 2008, when artemisinin-based combination therapy (ACT) were first introduced, with more mutations being observed in 2019, with two synonymous and five non-synonymous mutations being detected, although these are not related to resistance to ACT. In addition, the non-synonymous A578S mutation, which is the most frequent on the African continent, was detected in 2013, although not in the following years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Withdrawal of the use of chloroquine (CQ) as a treatment in Equatorial Guinea has been shown to be effective over time, as wild-type parasite populations outnumber mutant populations. The upward trend observed in sulfadoxine-pyrimethamine (SP) resistance markers suggest its misuse, either alone or in combination with artesunate (AS) or amodiaquine (AQ), in some areas of the country, as was found in a previous study conducted by this group, which allows selective pressure from SP to continue. Single nucleotide polymorphisms (SNPs) 540E and 581G do not exceed the limit of 50 and 10%, respectively, thus meaning that SP is still effective as an intermittent preventive treatment (IPT) in this country. As for the\n                      <jats:italic>pfk13<\/jats:italic>\n                      gene, no mutations have been detected in relation to resistance to ACT. However, in 2019 there is a greater accumulation of non-synonymous mutations compared to years prior to 2008.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12936-021-04000-w","type":"journal-article","created":{"date-parts":[[2021,12,14]],"date-time":"2021-12-14T05:02:55Z","timestamp":1639458175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Temporal evolution of the resistance genotypes of Plasmodium falciparum in isolates from Equatorial Guinea during 20\u00a0years (1999 to 2019)"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-717X","authenticated-orcid":false,"given":"Pedro","family":"Berzosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Molina de la Fuente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thuy-Huong","family":"Ta-Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicenta","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luz","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodr\u00edguez-Galet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n","family":"D\u00edaz-Rega\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Gal\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cerrada-G\u00e1lvez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Policarpo","family":"Ncogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Riloha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,14]]},"reference":[{"key":"4000_CR1","unstructured":"WHO. World Malaria Report 2020 [Internet]. Geneva, World Health Organization, 2020. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2020. Accessed 15 Jun 2021."},{"key":"4000_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI21682","volume":"113","author":"NJ White","year":"2004","unstructured":"White NJ. Antimalarial drug resistance. J Clin Invest. 2004;113:1084\u201392.","journal-title":"J Clin Invest"},{"key":"4000_CR3","volume-title":"Global Report on antimarial drug efficacy and drug resistance: 2000\u20132010","author":"WHO","year":"2010","unstructured":"WHO. Global Report on antimarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"4000_CR4","doi-asserted-by":"publisher","first-page":"781865","DOI":"10.1155\/2009\/781865","volume":"2009","author":"P Charle","year":"2009","unstructured":"Charle P, Berzosa P, Descalzo MA, de Lucio A, Raso J, Obono J, et al. Efficacy of artesunate + sulphadoxine-pyrimethamine (AS + SP) and amodiaquine + sulphadoxine-pyrimethamine (AQ + SP) for uncomplicated falciparum malaria in Equatorial Guinea (Central Africa). J Trop Med. 2009;2009:781865.","journal-title":"J Trop Med."},{"key":"4000_CR5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4269\/ajtmh.12-0290","volume":"88","author":"P Charle","year":"2013","unstructured":"Charle P, Berzosa P, de Lucio A, Raso J, Nseng Nchama G, Benito A. Artesunate\/amodiaquine malaria treatment for Equatorial Guinea (Central Africa). Am J Trop Med Hyg. 2013;88:1087\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"4000_CR6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1186\/s12936-021-03807-x","volume":"20","author":"MR Rivas","year":"2021","unstructured":"Rivas MR, Warsame M, Andeme RM, Esidang SN, Ncogo PR, Phiri WP, et al. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine and polymorphism in Plasmodium falciparum kelch13-propeller gene in Equatorial Guinea. Malar J. 2021;20:275.","journal-title":"Malar J"},{"key":"4000_CR7","unstructured":"WHO\/ Institute of Health Carlos III\/National Malaria Programme, Ministry of Health and Social Welfare of Equatorial Guinea. National Malaria Therapeutic Guidelines-Equatorial Guinea, Malobo, 2020."},{"key":"4000_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S1473-3099(03)00657-1","volume":"3","author":"EL Korenromp","year":"2003","unstructured":"Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis. 2003;3:349\u201358.","journal-title":"Lancet Infect Dis"},{"key":"4000_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/1475-2875-13-264","volume":"13","author":"RA Kavishe","year":"2014","unstructured":"Kavishe RA, Paulo P, Kaaya RD, Kalinga A, van Zwetselaar M, Chilongola J, et al. Surveillance of artemether-lumefantrine associated Plasmodium falciparum multidrug resistance protein-1 gene polymorphisms in Tanzania. Malar J. 2014;13:264.","journal-title":"Malar J"},{"key":"4000_CR10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1111\/febs.14127","volume":"284","author":"AM Thu","year":"2017","unstructured":"Thu AM, Phyo AP, Landier J, Parker DM, Nosten FH. Combating multidrug-resistant Plasmodium falciparum malaria. FEBS J. 2017;284:2569\u201378.","journal-title":"FEBS J"},{"key":"4000_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.meegid.2018.10.007","volume":"66","author":"MA Oboh","year":"2018","unstructured":"Oboh MA, Singh US, Antony HA, Ndiaye D, Badiane AS, Ali NA, et al. Molecular epidemiology and evolution of drug-resistant genes in the malaria parasite Plasmodium falciparum in southwestern Nigeria. Infect Genet Evol. 2018;66:222\u20138.","journal-title":"Infect Genet Evol"},{"key":"4000_CR12","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12936-018-2512-1","volume":"17","author":"M Henry","year":"2018","unstructured":"Henry M, Florey L, Youll S, Gutman JR. An analysis of country adoption and implementation of the 2012 WHO recommendations for intermittent preventive treatment for pregnant women in sub-Saharan Africa. Malar J. 2018;17:364.","journal-title":"Malar J"},{"key":"4000_CR13","unstructured":"WHO. Policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa. Geneva, World Health Organization; 2010; https:\/\/apps.who.int\/iris\/handle\/10665\/337977. Accessed 16 Jun 2021."},{"key":"4000_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12936-021-03693-3","volume":"20","author":"LN Amenga-Etego","year":"2021","unstructured":"Amenga-Etego LN, Asoala V, Agongo G, Jacob C, Goncalves S, Awandare GA, et al. Temporal evolution of sulfadoxine-pyrimethamine resistance genotypes and genetic diversity in response to a decade of increased interventions against Plasmodium falciparum in northern Ghana. Malar J. 2021;20:152.","journal-title":"Malar J"},{"key":"4000_CR15","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/jac\/dky258","volume":"73","author":"P Nkoli Mandoko","year":"2018","unstructured":"Nkoli Mandoko P, Rouvier F, Matendo Kakina L, Moke Mbongi D, Latour C, Losimba Likwela J, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine\/pyrimethamine in the Democratic Republic of the Congo: emergence of highly resistant pfdhfr\/pfdhps alleles. J Antimicrob Chemother. 2018;73:2704\u201315.","journal-title":"J Antimicrob Chemother"},{"key":"4000_CR16","first-page":"38","volume":"16","author":"M Cisse","year":"2017","unstructured":"Cisse M, Awandare GA, Soulama A, Tinto H, Hayette M-P, Guiguemd\u00e9 RT. Recent uptake of intermittent preventive treatment during pregnancy with sulfadoxine-pyrimethamine is associated with increased prevalence of Pfdhfr mutations in Bobo-Dioulasso. Burkina Faso Malar J. 2017;16:38.","journal-title":"Burkina Faso Malar J"},{"key":"4000_CR17","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00436-018-5754-5","volume":"117","author":"E Esu","year":"2018","unstructured":"Esu E, Tacoli C, Gai P, Berens-Riha N, Pritsch M, Loescher T, et al. Prevalence of the Pfdhfr and Pfdhps mutations among asymptomatic pregnant women in Southeast Nigeria. Parasitol Res. 2018;117:801\u20137.","journal-title":"Parasitol Res"},{"key":"4000_CR18","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.pt.2013.08.002","volume":"29","author":"I Naidoo","year":"2013","unstructured":"Naidoo I, Roper C. Mapping, \u201cpartially resistant\u201d, \u201cfully resistant\u201d, and \u201csuper resistant\u201d malaria. Trends Parasitol. 2013;29:505\u201315.","journal-title":"Trends Parasitol"},{"key":"4000_CR19","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12936-017-1783-2","volume":"16","author":"NT Ndam","year":"2017","unstructured":"Ndam NT, Basco LK, Ngane VF, Ayouba A, Ngolle EM, Deloron P, et al. Reemergence of chloroquine-sensitive pfcrt K76 Plasmodium falciparum genotype in southeastern Cameroon. Malar J. 2017;16:130.","journal-title":"Malar J"},{"key":"4000_CR20","first-page":"7071383","volume":"2018","author":"MN Moyeh","year":"2018","unstructured":"Moyeh MN, Njimoh DL, Evehe MS, Ali IM, Nji AM, Nkafu DN, et al. Effects of drug policy changes on evolution of molecular markers of Plasmodium falciparum resistance to chloroquine, amodiaquine, and sulphadoxine-pyrimethamine in the south west Region of Cameroon. Malar Res Treat. 2018;2018:7071383.","journal-title":"Malar Res Treat"},{"key":"4000_CR21","first-page":"195","volume":"1","author":"SA Omar","year":"2007","unstructured":"Omar SA, Makokha WF, Saif A, Kimani F, Magoma G. Prevalence of Plasmodium falciparum chloroquine resistant gene markers, pfcrt-76 and pfmdr1-86, eight years after cessation of chloroquine use in Mwea, Kenya. J Infect Develop Countries. 2007;1:195\u2013201.","journal-title":"J Infect Develop Countries"},{"key":"4000_CR22","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1086\/375419","volume":"187","author":"JG Kublin","year":"2003","unstructured":"Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870\u20135.","journal-title":"J Infect Dis"},{"key":"4000_CR23","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJMoa062032","volume":"355","author":"MK Laufer","year":"2006","unstructured":"Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959\u201366.","journal-title":"N Engl J Med"},{"key":"4000_CR24","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4269\/ajtmh.2006.75.155","volume":"75","author":"CT Happi","year":"2006","unstructured":"Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am J Trop Med Hyg. 2006;75:155\u201361.","journal-title":"Am J Trop Med Hyg."},{"key":"4000_CR25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12936-019-2977-6","volume":"18","author":"MN Ikegbunam","year":"2019","unstructured":"Ikegbunam MN, Nkonganyi CN, Thomas BN, Esimone CO, Velavan TP, Ojurongbe O. Analysis of Plasmodium falciparum Pfcrt and Pfmdr1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine. Malar J. 2019;18:343.","journal-title":"Malar J"},{"key":"4000_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12936-019-2701-6","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors. Malar J. 2019;18:60.","journal-title":"Malar J"},{"key":"4000_CR27","unstructured":"WHO. Strategy for malaria elimination in the Greater Mekong Subregion\u202f: 2015\u20132030 [Internet]. Manila\u202f: WHO Regional Office for the Western Pacif2015. https:\/\/apps.who.int\/iris\/handle\/10665\/208203. Accessed 16 Jun 2021."},{"key":"4000_CR28","unstructured":"WHO. Artemisinin resistance and artemisin-based combination therapy efficacy. WHO-CDS-GMP-2018.18-eng.pdf. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274362\/WHO-CDS-GMP-2018.18-eng.pdf?ua=1. Accessed 16 Jun 2021."},{"key":"4000_CR29","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"4000_CR30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1126\/science.1215966","volume":"336","author":"IH Cheeseman","year":"2012","unstructured":"Cheeseman IH, Miller BA, Nair S, Nkhoma S, Tan A, Tan JC, et al. A major genome region underlying artemisinin resistance in malaria. Science. 2012;336:79\u201382.","journal-title":"Science"},{"key":"4000_CR31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"4000_CR32","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"4000_CR33","doi-asserted-by":"publisher","first-page":"e08714","DOI":"10.7554\/eLife.08714","volume":"5","author":"MalariaGEN Plasmodium falciparum Community Project","year":"2016","unstructured":"MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. eLife. 2016;5:e08714.","journal-title":"eLife."},{"key":"4000_CR34","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211:1352\u20135.","journal-title":"J Infect Dis"},{"key":"4000_CR35","doi-asserted-by":"publisher","first-page":"e105690","DOI":"10.1371\/journal.pone.0105690","volume":"9","author":"MD Conrad","year":"2014","unstructured":"Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya MR, Havlir DV, et al. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;9:e105690.","journal-title":"PLoS ONE."},{"key":"4000_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","volume":"18","author":"DS Ishengoma","year":"2019","unstructured":"Ishengoma DS, Mandara CI, Francis F, Talundzic E, Lucchi NW, Ngasala B, et al. Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania. Malar J. 2019;18:88.","journal-title":"Malar J"},{"key":"4000_CR37","doi-asserted-by":"publisher","first-page":"e0221895","DOI":"10.1371\/journal.pone.0221895","volume":"14","author":"CE Eboumbou Moukoko","year":"2019","unstructured":"Eboumbou Moukoko CE, Huang F, Nsango SE, Kojom Foko LP, Ebong SB, Epee Eboumbou P, et al. K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian Plasmodium falciparum malaria patients. PLoS ONE. 2019;14:e0221895.","journal-title":"PLoS ONE."},{"key":"4000_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/1475-2875-13-68","volume":"13","author":"TH Ta","year":"2014","unstructured":"Ta TH, Hisam S, Lanza M, Jiram AI, Ismail N, Rubio JM. First case of a naturally acquired human infection with Plasmodium cynomolgi. Malar J. 2014;13:68.","journal-title":"Malar J"},{"issue":"Suppl 1","key":"4000_CR39","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1016\/S0035-9203(02)90077-5","volume":"96","author":"JM Rubio","year":"2002","unstructured":"Rubio JM, Post RJ, van Leeuwen WMD, Henry MC, Lindergard G, Hommel M. Alternative polymerase chain reaction method to identify Plasmodium species in human blood samples: the semi-nested multiplex malaria PCR (SnM-PCR). Trans R Soc Trop Med Hyg. 2002;96(Suppl 1):S199-204.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4000_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4269\/ajtmh.1995.52.565","volume":"52","author":"CV Plowe","year":"1995","unstructured":"Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"4000_CR41","unstructured":"Protocols. University of Maryland School of Medicine. https:\/\/www.medschool.umaryland.edu\/malaria\/protocols\/. Accessed 16 Jun 2021."},{"key":"4000_CR42","unstructured":"Menard D, Ariey F. PCR_sequencing for genotyping SNPs PF3D7_1343700 Kelch protein propeller domain. Protocol Exchange. 2013; http:\/\/www.nature.com\/protocolexchange\/protocols\/2927. Accessed 16 Jun 2021."},{"key":"4000_CR43","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S0022-2836(05)80360-2","volume":"215","author":"SF Altschul","year":"1990","unstructured":"Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215:403\u201310.","journal-title":"J Mol Biol"},{"key":"4000_CR44","doi-asserted-by":"publisher","first-page":"526","DOI":"10.4269\/ajtmh.1995.53.526","volume":"53","author":"A Benito","year":"1995","unstructured":"Benito A, Roche J, Molina R, Amela C, Alvar J. In vitro susceptibility of Plasmodium falciparum to chloroquine, amodiaquine, quinine, mefloquine, and sulfadoxine\/pyrimethamine in Equatorial Guinea. Am J Trop Med Hyg. 1995;53:526\u201331.","journal-title":"Am J Trop Med Hyg"},{"key":"4000_CR45","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4269\/ajtmh.2003.68.598","volume":"68","author":"J Roche","year":"2003","unstructured":"Roche J, Guerra-Neira A, Raso J, Benito A. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). Am J Trop Med Hyg. 2003;68:598\u2013601.","journal-title":"Am J Trop Med Hyg"},{"key":"4000_CR46","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1097-2765(05)00077-8","volume":"6","author":"DA Fidock","year":"2000","unstructured":"Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6:861\u201371.","journal-title":"Mol Cell."},{"key":"4000_CR47","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijpddr.2015.05.005","volume":"5","author":"AO Achieng","year":"2015","unstructured":"Achieng AO, Muiruri P, Ingasia LA, Opot BH, Juma DW, Yeda R, et al. Temporal trends in prevalence of Plasmodium falciparum molecular markers selected for by artemether-lumefantrine treatment in pre-ACT and post-ACT parasites in western Kenya. Int J Parasitol Drugs Drug Resist. 2015;5:92\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4000_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12936-019-2716-z","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. Persistence of chloroquine resistance alleles in malaria endemic countries: a systematic review of burden and risk factors. Malar J. 2019;18:76.","journal-title":"Malar J"},{"key":"4000_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.ijpddr.2020.10.009","volume":"14","author":"ST Windle","year":"2020","unstructured":"Windle ST, Lane KD, Gadalla NB, Liu A, Mu J, Caleon RL, et al. Evidence for linkage of pfmdr1, pfcrt, and pfk13 polymorphisms to lumefantrine and mefloquine susceptibilities in a Plasmodium falciparum cross. Int J Parasitol Drugs Drug Resist. 2020;14:208\u201317.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"4000_CR50","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1086\/427997","volume":"191","author":"C Sisowath","year":"2005","unstructured":"Sisowath C, Str\u00f6mberg J, M\u00e5rtensson A, Msellem M, Obondo C, Bj\u00f6rkman A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis. 2005;191:1014\u20137.","journal-title":"J Infect Dis"},{"key":"4000_CR51","doi-asserted-by":"publisher","first-page":"e64299","DOI":"10.1371\/journal.pone.0064299","volume":"8","author":"FL Eyase","year":"2013","unstructured":"Eyase FL, Akala HM, Ingasia L, Cheruiyot A, Omondi A, Okudo C, et al. The role of Pfmdr1 and Pfcrt in changing chloroquine, amodiaquine, mefloquine and lumefantrine susceptibility in western-Kenya P. falciparum samples during 2008\u20132011. PLoS ONE. 2013;8:e64299.","journal-title":"PLoS ONE."},{"key":"4000_CR52","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/infdis\/jiu141","volume":"210","author":"MD Conrad","year":"2014","unstructured":"Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J Infect Dis. 2014;210:344\u201353.","journal-title":"J Infect Dis"},{"key":"4000_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4269\/ajtmh.14-0031","volume":"91","author":"M Venkatesan","year":"2014","unstructured":"Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al. Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg. 2014;91:833\u201343.","journal-title":"Am J Trop Med Hyg."},{"key":"4000_CR54","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1128\/AAC.03647-14","volume":"59","author":"V Baraka","year":"2015","unstructured":"Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob Agents Chemother. 2015;59:734\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"4000_CR55","doi-asserted-by":"publisher","first-page":"e6762","DOI":"10.1371\/journal.pone.0006762","volume":"4","author":"DJ Bacon","year":"2009","unstructured":"Bacon DJ, Tang D, Salas C, Roncal N, Lucas C, Gerena L, et al. Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine. PLoS ONE. 2009;4:e6762.","journal-title":"PLoS ONE."},{"key":"4000_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12936-016-1672-0","volume":"16","author":"P Berzosa","year":"2017","unstructured":"Berzosa P, Esteban-Cantos A, Garc\u00eda L, Gonz\u00e1lez V, Navarro M, Fern\u00e1ndez T, et al. Profile of molecular mutations in pfdhfr, pfdhps, pfmdr1, and pfcrt genes of Plasmodium falciparum related to resistance to different anti-malarial drugs in the Bata District (Equatorial Guinea). Malar J. 2017;16:28.","journal-title":"Malar J"},{"key":"4000_CR57","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2147\/IDR.S236898","volume":"13","author":"L-Y Lin","year":"2020","unstructured":"Lin L-Y, Li J, Huang H-Y, Liang X-Y, Jiang T-T, Chen J-T, et al. Trends in molecular markers associated with resistance to sulfadoxine-pyrimethamine (SP) among Plasmodium falciparum isolates on Bioko Island, Equatorial Guinea: 2011\u20132017. Infect Drug Resist. 2020;13:1203\u201312.","journal-title":"Infect Drug Resist"},{"key":"4000_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12936-018-2254-0","volume":"17","author":"M Romay-Barja","year":"2018","unstructured":"Romay-Barja M, Ncogo P, Nseng G, Santana-Morales MA, Berzosa P, Herrador Z, et al. The use and preference of artemether as a first-choice treatment for malaria: results from a cross-sectional survey in the Bata district, Equatorial Guinea. Malar J. 2018;17:107.","journal-title":"Malar J"},{"key":"4000_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12936-017-2160-x","volume":"17","author":"E Ruh","year":"2018","unstructured":"Ruh E, Bateko JP, Imir T, Taylan-Ozkan A. Molecular identification of sulfadoxine-pyrimethamine resistance in malaria infected women who received intermittent preventive treatment in the Democratic Republic of Congo. Malar J. 2018;17:17.","journal-title":"Malar J"},{"key":"4000_CR60","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.2147\/IDR.S160164","volume":"11","author":"DF Voumbo-Matoumona","year":"2018","unstructured":"Voumbo-Matoumona DF, Kouna LC, Madamet M, Maghendji-Nzondo S, Pradines B, Lekana-Douki JB. Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014. Infect Drug Resist. 2018;11:1329\u201338.","journal-title":"Infect Drug Resist"},{"key":"4000_CR61","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1093\/jac\/dkv160","volume":"70","author":"P Chauvin","year":"2015","unstructured":"Chauvin P, Menard S, Iriart X, Nsango SE, Tchioffo MT, Abate L, et al. Prevalence of Plasmodium falciparum parasites resistant to sulfadoxine\/pyrimethamine in pregnant women in Yaound\u00e9, Cameroon: emergence of highly resistant pfdhfr\/pfdhps alleles. J Antimicrob Chemother. 2015;70:2566\u201371.","journal-title":"J Antimicrob Chemother"},{"key":"4000_CR62","unstructured":"Ministry of Health and Social Welfare of Equatorial Guinea, National Malaria Programme, Equatorial Guinea, National Centre of Tropical Medicine, Institute of Health Carlos III (Spain). Evaluation of the efficacy of artesunate+amodiaquine in uncomplicated Plasmodium falciparum malaria (2010). National Programme of Malaria (Equatorial Guinea)\/ National Centre of Tropical Medicine (ISCIII) (Spain), 2011."},{"key":"4000_CR63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12936-018-2370-x","volume":"17","author":"K Banek","year":"2018","unstructured":"Banek K, Webb EL, Smith SJ, Chandramohan D, Staedke SG. Adherence to treatment with artemether-lumefantrine or amodiaquine-artesuate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malar J. 2018;17:222.","journal-title":"Malar J"},{"key":"4000_CR64","doi-asserted-by":"publisher","first-page":"465","DOI":"10.7883\/yoken.65.465","volume":"65","author":"T Mita","year":"2012","unstructured":"Mita T, Tanabe K. Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance. Jpn J Infect Dis. 2012;65:465\u201375.","journal-title":"Jpn J Infect Dis"},{"key":"4000_CR65","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/1475-2875-13-472","volume":"13","author":"M Torrentino-Madamet","year":"2014","unstructured":"Torrentino-Madamet M, Fall B, Benoit N, Camara C, Amalvict R, Fall M, et al. Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012\u20132013. Malar J. 2014;13:472.","journal-title":"Malar J"},{"key":"4000_CR66","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4269\/ajtmh.16-0889","volume":"97","author":"JA Djaman","year":"2017","unstructured":"Djaman JA, Olefongo D, Ako AB, Roman J, Ngane VF, Basco LK, et al. Molecular epidemiology of malaria in Cameroon and C\u00f4te d\u2019Ivoire. XXXI. Kelch 13 propeller sequences in Plasmodium falciparum isolates before and after implementation of artemisinin-based combination therapy. Am J Trop Med Hyg. 2017;97:222\u20134.","journal-title":"Am J Trop Med Hyg."},{"key":"4000_CR67","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.4269\/ajtmh.17-0505","volume":"98","author":"ZR de Laurent","year":"2018","unstructured":"de Laurent ZR, Chebon LJ, Ingasia LA, Akala HM, Andagalu B, Ochola-Oyier LI, et al. Polymorphisms in the K13 gene in Plasmodium falciparum from different malaria transmission areas of Kenya. Am J Trop Med Hyg. 2018;98:1360\u20136.","journal-title":"Am J Trop Med Hyg"},{"key":"4000_CR68","doi-asserted-by":"crossref","unstructured":"Safeukui I, Fru-Cho J, Mbengue A, Suresh N, Njimoh DL, Bumah VV, et al. Investigation of polymorphisms in the P. falciparum artemisinin resistance marker kelch13 in asymptomatic infections in a rural area of Cameroon. bioRxiv. Cold Spring Harbor Laboratory; 2017;148999.","DOI":"10.1101\/148999"},{"key":"4000_CR69","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijpddr.2015.11.002","volume":"6","author":"J Li","year":"2016","unstructured":"Li J, Chen J, Xie D, Eyi UM, Matesa RA, Ondo Obono MM, et al. Limited artemisinin resistance-associated polymorphisms in Plasmodium falciparum K13-propeller and PfATPase6 gene isolated from Bioko Island, Equatorial Guinea. Int J Parasitol Drugs Drug Resist. 2016;6:54\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-04000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-04000-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-04000-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T01:07:30Z","timestamp":1666746450000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-04000-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,14]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["4000"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-04000-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-903234\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-903234\/v1","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,14]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All samples are part of a collection deposited in the sample pool of the Institute of Health Carlos III (ISCIII) of the National Centre of Tropical Medicine. The samples were taken inside of different projects that were carried out in Equatorial Guinea. The Ethics Committee of the ISCIII and the Ministry of Health and Social Welfare of Equatorial Guinea approved these projects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to the publication of the manuscript, and there are not any competing interests. All authors read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"463"}}